Coherus Operating Margin from 2010 to 2024
| CHRS Stock | USD 1.21 0.12 11.01% |
Check Coherus BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coherus BioSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 42.6 M or Selling General Administrative of 100.1 M, as well as many indicators such as Price To Sales Ratio of 1.16, Dividend Yield of 0.0 or Days Sales Outstanding of 388. Coherus financial statements analysis is a perfect complement when working with Coherus BioSciences Valuation or Volatility modules.
Coherus | Operating Margin |
Latest Coherus BioSciences' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Coherus BioSciences over the last few years. It is Coherus BioSciences' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coherus BioSciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.09) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Coherus Operating Margin Regression Statistics
| Arithmetic Mean | (24.50) | |
| Coefficient Of Variation | (195.08) | |
| Mean Deviation | 30.87 | |
| Median | (2.08) | |
| Standard Deviation | 47.79 | |
| Sample Variance | 2,284 | |
| Range | 150 | |
| R-Value | 0.1 | |
| Mean Square Error | 2,437 | |
| R-Squared | 0.01 | |
| Significance | 0.73 | |
| Slope | 1.03 | |
| Total Sum of Squares | 31,979 |
Coherus Operating Margin History
About Coherus BioSciences Financial Statements
Coherus BioSciences shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Coherus BioSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Coherus BioSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coherus BioSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 368 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.